This study will collect de-identified tumor samples, with correlated clinical/demographic
data and tissue histology, from patients selected or scheduled for pre-treatment tumor
biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical
data may be used in subsequent studies for the development and validation of a diagnostic
test.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04510129.
Locations matching your search criteria
United States
California
Palo Alto
Stanford Cancer Institute Palo AltoStatus: Active
Name Not Available
This study will establish a prospective cohort of pre-treatment tumor specimens with
correlated de-identified clinical and demographic data and tissue histology from cancer
patients who are undergoing treatment with PD-1/PD-L1 inhibitors. Patients who have
undergone pre-anti-PD-1/PD-L1-treatment tumor biopsy or who are scheduled for tumor
biopsy prior to anti-PD-1/PD-L1 treatment will be enrolled.
The study will not require a study-specific tumor biopsy; any biopsies taken prior to
treatment as part of standard of care are eligible for this study. Biopsies must not have
been taken after immunotherapy treatment began.
Participants will be asked to provide their consent for the potential use of their
biospecimens in subsequent studies for the development and validation of a diagnostic
test.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationCofactor Genomics, Inc.
